CN111110721A - 一种毛发防脱再生的复合制剂及其使用方法 - Google Patents
一种毛发防脱再生的复合制剂及其使用方法 Download PDFInfo
- Publication number
- CN111110721A CN111110721A CN202010057066.XA CN202010057066A CN111110721A CN 111110721 A CN111110721 A CN 111110721A CN 202010057066 A CN202010057066 A CN 202010057066A CN 111110721 A CN111110721 A CN 111110721A
- Authority
- CN
- China
- Prior art keywords
- hair
- parts
- compound preparation
- injection
- hair loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000011069 regeneration method Methods 0.000 title claims abstract description 5
- 150000001875 compounds Chemical class 0.000 title claims description 16
- 230000003658 preventing hair loss Effects 0.000 title claims description 7
- 230000003660 hair regeneration Effects 0.000 title claims description 4
- 239000007924 injection Substances 0.000 claims abstract description 17
- 238000002347 injection Methods 0.000 claims abstract description 17
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 10
- 229960003632 minoxidil Drugs 0.000 claims abstract description 10
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 9
- 239000011720 vitamin B Substances 0.000 claims abstract description 9
- 229940046001 vitamin b complex Drugs 0.000 claims abstract description 8
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims abstract description 7
- 239000002131 composite material Substances 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 3
- 201000004384 Alopecia Diseases 0.000 claims description 14
- 210000004761 scalp Anatomy 0.000 claims description 8
- 230000003676 hair loss Effects 0.000 claims description 7
- 231100000360 alopecia Toxicity 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 208000024963 hair loss Diseases 0.000 claims description 6
- 230000035515 penetration Effects 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 230000001172 regenerating effect Effects 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 238000002054 transplantation Methods 0.000 abstract description 2
- 230000003656 anti-hair-loss Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 5
- 239000005515 coenzyme Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 244000132619 red sage Species 0.000 description 4
- 239000003098 androgen Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- DVCLGDDFGUFHPE-UHFFFAOYSA-N 6-pyrrolidin-1-ylpyrimidine-2,4-diamine Chemical compound NC1=NC(N)=CC(N2CCCC2)=N1 DVCLGDDFGUFHPE-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种毛发防脱再生的复合制剂及其使用方法，其特征在于，包括以下重量比例的原料组成：5％米诺地尔溶液5份、复合维生素B注射液2份和丹参注射液10份。本发明与现有技术相比的优点在于：解决了外涂产品效果不确切，持续时间短；口服药物对全身副作用大且效果也不显著；毛发移植创伤大，且取材数量受局限等不足，采用注射的方式进行药液涂抹，更加接近毛囊处，具有很强的针对性。
Description
技术领域
本发明涉及生发剂领域，具体是指一种毛发防脱再生的复合制剂及其使用方法。
背景技术
脱发是指头发脱落的现象。正常脱落的头发都是处于退行期及休止期的毛发，由于进入退行期与新进入生长期的毛发不断处于动态平衡，故能维持正常数量的头发。病理性脱发是指头发异常或过度的脱落，其原因很多。随着生活节奏的加快，年轻人熬夜加班、学习、熬夜，促使头发迅速脱落，脱发已经越来越年轻化了，但是目前的脱发防治采用的大多是洗液之类的，通过皮肤直接接触，但是药液进入头皮过程就会造成分散，没法全部进入头皮内部。
发明内容
本发明要解决的技术问题是，针对以上问题，提供一种能够突破传统单纯外用涂抹进行毛发防脱再生的方法。
为解决上述技术问题，本发明提供的技术方案为：一种毛发防脱再生的复合制剂及其使用方法，其特征在于，包括以下重量比例的原料组成：5％米诺地尔溶液5份、复合维生素B注射液2份和丹参注射液10份。
作为优选的，所述使用方法为：
(1)配制复合制剂：5％米诺地尔溶液、复合维生素B注射液、丹参注射液按照5:2:10的比例进行配制；
(2)稀释复合制剂：用0.9％生理盐水把复合制剂进行10倍稀释；
(3)脱发区精准导入：用纳米微针在脱发区进行靶向精准渗透把复合制剂导入到头皮内的毛囊区域。
本发明与现有技术相比的优点在于：解决了外涂产品效果不确切，持续时间短；口服药物对全身副作用大且效果也不显著；毛发移植创伤大，且取材数量受局限等不足，采用注射的方式进行药液涂抹，更加接近毛囊处，具有很强的针对性。
具体实施方式
本发明在具体实施时，一种毛发防脱再生的复合制剂及其使用方法，其特征在于，包括以下重量比例的原料组成：5％米诺地尔溶液5份、复合维生素B注射液2份和丹参注射液10份。
作为优选的，所述使用方法为：
(1)配制复合制剂：5％米诺地尔溶液、复合维生素B注射液、丹参注射液按照5:2:10的比例进行配制；
(2)稀释复合制剂：用0.9％生理盐水把复合制剂进行10倍稀释；
(3)脱发区精准导入：用纳米微针在脱发区进行靶向精准渗透把复合制剂导入到头皮内的毛囊区域。
本发明的工作原理：米诺地尔，化学名为6-(1-哌啶基)-2,4-嘧啶二胺,3-氧化物，为白色或类白色结晶性粉末。在乙醇中略溶，在三氯甲烷或水中微溶，在丙酮中极微溶解；在冰醋酸中溶解。临床上作为钾离子通道开放剂，能直接松弛血管平滑肌，有强大的小动脉扩张作用，使外周阻力下降，血压下降，而对容量血管无影响，故能促进静脉回流。同时，由于反射性调节作用和米诺地尔可以直接刺激毛囊上皮细胞增殖和分化，促进毛发生长；促进血管形成，增加局部血流量，给毛发生长提供营养；开放钾离子通道；使毛囊由休止期向生长期转化。已有充分的临床试验证实米诺地尔对雄激素性脱发、斑秃有较好的疗效，但是常规外用方法吸收率太低。
复合维生素B参与机体新陈代谢过程，为体内多种代谢环节所必需的辅酶和提供组织呼吸的重要辅酶。维生素B1是碳水化合物代谢所需辅酶的重要组成成分。维生素B2为组织呼吸所需的重要辅酶组成成分。维生素B6为多种酶的辅基，参与氨基酸及脂肪的代谢。烟酰胺为辅酶Ⅰ及Ⅱ的组分，为脂质代谢、组织呼吸的氧化作用和糖原分解所必需。泛酸钠为辅酶A的前体，参与碳水化合物、脂肪、蛋白质的代谢。B族维生素与上皮组织、皮脂代谢、头皮炎症控制有密切关系，而且容易缺乏。
丹参，中药名。为唇形科植物，具有活血祛瘀，通经止痛，清心除烦，凉血消痈之功效。用于胸痹心痛，脘腹胁痛，症瘕积聚，热痹疼痛，心烦不眠，月经不调，痛经经闭，疮疡肿痛。丹参注射液中含有丹参酮，后者具有拮抗雄激素合成作，抑制雄性激素的过度表达，竞争毛囊的双氢睾酮受体，从而减弱雄激素对毛囊生长的影响，抑制促毛发凋亡因子；同时又活血化瘀功效，可改善头皮微循环，促进局部头皮的新陈代谢，具有抗炎抑菌和防止毛囊周围纤维化等功效。
此外，术语“第一”、“第二”仅用于描述目的，而不能理解为指示或暗示相对重要性或者隐含指明所指示的技术特征的数量。由此，限定有“第一”、“第二”的特征可以明示或者隐含地包括一个或者更多个该特征，在本发明的描述中，“多个”的含义是两个或两个以上，除非另有明确具本的限定。
在本发明中，除非另有明确的规定和限定，术语“安装”、“相连”、“连接”、“固定”等术语应做广义理解，例如，可以是固定连接，也可以是可拆卸连接或一体地连接；可以是机械连接，也可以是电连接；可以是直接相连，也可以通过中间媒介间接相连，可以是两个元件内部的连通。对于本领域的普通技术人员而言，可以根据具体情况理解上述术语在本发明中的具体含义。
在本发明中，除非另有明确的规定和限定，第一特征在第二特征之“上”或之“下”可以包括第一和第二特征直接接触，也可以包括第一和第二特征不是直接接触而是通过它们之间的另外的特征接触。而且，第一特征在第二特征“之上”、“上方”和“上面”包括第一特征在第二特征正上方和斜上方，或仅仅表示第一特征水平高度高于第二特征。第一特征在第二特征“之下”、“下方”和“下面”包括第一特征在第二特征正上方和斜上方，或仅仅表示第一特征水平高度小于第二特征。
在本说明书的描述中，参考术语“一个实施例”、“一些实施例”、“示例”，“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中，对上述术语的示意性表述不一定指的是相同的实施例或示例。而且，描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
尽管上面已经示出和描述了本发明的实施例，可以理解的是，上述实施例是示例性的，不能理解为对本发明的限制，本领域的普通技术人员在不脱离本发明的原理和宗旨的情况下在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (2)
1.一种毛发防脱再生的复合制剂及其使用方法，其特征在于，包括以下重量比例的原料组成：5％米诺地尔溶液5份、复合维生素B注射液2份和丹参注射液10份。
2.根据权利要求1所述的一种毛发防脱再生的复合制剂及其使用方法，其特征在于，所述使用方法为：(1)配制复合制剂：5％米诺地尔溶液、复合维生素B注射液、丹参注射液按照5:2:10的比例进行配制；
(2)稀释复合制剂：用0.9％生理盐水把复合制剂进行10倍稀释；
(3)脱发区精准导入：用纳米微针在脱发区进行靶向精准渗透把复合制剂导入到头皮内的毛囊区域。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010057066.XA CN111110721A (zh) | 2020-01-19 | 2020-01-19 | 一种毛发防脱再生的复合制剂及其使用方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010057066.XA CN111110721A (zh) | 2020-01-19 | 2020-01-19 | 一种毛发防脱再生的复合制剂及其使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111110721A true CN111110721A (zh) | 2020-05-08 |
Family
ID=70490211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010057066.XA Pending CN111110721A (zh) | 2020-01-19 | 2020-01-19 | 一种毛发防脱再生的复合制剂及其使用方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111110721A (zh) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726902A (zh) * | 2005-07-26 | 2006-02-01 | 钟健琳 | 一种毛发促进生长剂的组方及应用 |
| CN101453985A (zh) * | 2006-03-28 | 2009-06-10 | 诺华丝国际股份有限公司 | 促进毛发生长的组合物 |
| CN101646423A (zh) * | 2006-12-28 | 2010-02-10 | 金知活 | 用于防止脱发和促进头发生长的纳米颗粒组合物 |
| CN103596550A (zh) * | 2011-04-25 | 2014-02-19 | 朴俊炯 | 用于预防脱发和促进毛发生长的局部施用的组合物 |
| CN103747775A (zh) * | 2011-01-31 | 2014-04-23 | 阿勒根公司 | 促进毛发生长的方法 |
| CN105641478A (zh) * | 2016-04-01 | 2016-06-08 | 杜晓生 | 用于治疗脱发的中药组合物、中药口服剂及其制备方法 |
| CN106138058A (zh) * | 2016-08-15 | 2016-11-23 | 颜晓丽 | 一种毛发生长诱导剂 |
| CN107106560A (zh) * | 2014-10-29 | 2017-08-29 | 萨姆森临床私人有限公司 | 毛发过度脱落的检测和治疗 |
| CN107281185B (zh) * | 2017-06-16 | 2018-08-17 | 曹凡 | 一种促进毛发生长的乳化组合物及其制备方法 |
| CN109260121A (zh) * | 2018-11-28 | 2019-01-25 | 广东万诺达药妆生物科技有限公司 | 一种防脱育发的原料配方 |
-
2020
- 2020-01-19 CN CN202010057066.XA patent/CN111110721A/zh active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726902A (zh) * | 2005-07-26 | 2006-02-01 | 钟健琳 | 一种毛发促进生长剂的组方及应用 |
| CN101453985A (zh) * | 2006-03-28 | 2009-06-10 | 诺华丝国际股份有限公司 | 促进毛发生长的组合物 |
| CN101646423A (zh) * | 2006-12-28 | 2010-02-10 | 金知活 | 用于防止脱发和促进头发生长的纳米颗粒组合物 |
| CN103747775A (zh) * | 2011-01-31 | 2014-04-23 | 阿勒根公司 | 促进毛发生长的方法 |
| CN103596550A (zh) * | 2011-04-25 | 2014-02-19 | 朴俊炯 | 用于预防脱发和促进毛发生长的局部施用的组合物 |
| CN107106560A (zh) * | 2014-10-29 | 2017-08-29 | 萨姆森临床私人有限公司 | 毛发过度脱落的检测和治疗 |
| CN105641478A (zh) * | 2016-04-01 | 2016-06-08 | 杜晓生 | 用于治疗脱发的中药组合物、中药口服剂及其制备方法 |
| CN106138058A (zh) * | 2016-08-15 | 2016-11-23 | 颜晓丽 | 一种毛发生长诱导剂 |
| CN107281185B (zh) * | 2017-06-16 | 2018-08-17 | 曹凡 | 一种促进毛发生长的乳化组合物及其制备方法 |
| CN109260121A (zh) * | 2018-11-28 | 2019-01-25 | 广东万诺达药妆生物科技有限公司 | 一种防脱育发的原料配方 |
Non-Patent Citations (3)
| Title |
|---|
| 季琛，等。: ""纳米微针的基本原理及在皮肤美容领域的临床应用"", 《现代中西医结合杂志》 * |
| 杜智敏主编: "《青藏高原疾病知识手册》", 28 February 1994 * |
| 马振友等主编: "《皮肤美容化妆品制剂手册》", 31 January 2015 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2470677C1 (ru) | Способ стимуляции репаративных и трофических процессов в коже | |
| US9782438B2 (en) | Method of promoting hair growth by administration of BFGF | |
| CN110302223B (zh) | 一种用于修复毛囊的育发液制剂及其制备方法 | |
| US9622963B2 (en) | Methods for stimulating growth and preventing loss of human hair | |
| KR20070092052A (ko) | 모발 성장 촉진 조성물 | |
| JP2000515112A (ja) | 毛髪成長刺激組成 | |
| CN112870333A (zh) | 一种改善人脱发生发的组合物、制剂及制备方法和应用 | |
| KR101698922B1 (ko) | 발모 및 육모 촉진용 조성물 | |
| CN113797142A (zh) | 一种薰衣草乳香黑曜精华液配方及其制备方法 | |
| CN111110721A (zh) | 一种毛发防脱再生的复合制剂及其使用方法 | |
| KR101484033B1 (ko) | 땅콩 껍질 추출물을 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| CN116370589B (zh) | 一种防脱育发组合物的制备方法和应用 | |
| CN106937957A (zh) | 一种用于治疗雄激素性脱发的配方、洗发液以及该配方的使用方法 | |
| KR100753437B1 (ko) | 홍삼 조사포닌과 감초,비오틴(Biotin),쿠퍼 펩타이드(Copper peptide), 사이토카인(Cytokines)을 함유한 나노 리포좀 입자 및 이를 함유한 헤어 케어용 화장료 | |
| KR20140091376A (ko) | 국화 추출물을 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| EP4134093A1 (en) | Peptide for preventing or treating hair loss, and use thereof | |
| KR101167510B1 (ko) | 인삼 사포닌 대사체를 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| TW200526222A (en) | Method of stimulating hair growth | |
| JP5730328B2 (ja) | 育毛剤組成物 | |
| CN113633585B (zh) | 具有防脱发、生发及黑发功效的外用护发组合物、制剂及其制备方法 | |
| CN113181145A (zh) | 姜酮在制备治疗脱发的药物或制剂中的应用 | |
| CN106344634B (zh) | 一种芒果皮提取物及其制备方法和用途 | |
| KR20180080368A (ko) | 모발 성장 촉진제 | |
| CN117357446B (zh) | 一种防脱发组合物及其方法和应用 | |
| CN115282137B (zh) | 一种外用擦剂护理组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200508 |